【摘要】 [目的]探讨survivin基因启动子区rs9904341位点多态性与肺癌发生风险和晚期非小细胞肺癌(NSCLC)患者铂类药物化疗疗效的关系。[方法]通过聚合酶链反应—限制性酶切片断多态性方法(PCR-RFLP)检测289例健康对照组和289例肺癌患者的rs9904341多态性的基因型;其中130例晚期NSCLC仅接受铂类药物化疗,分析经2个周期化疗后的疗效及基因型与铂类药物化疗疗效和生存期的关系。[结果]基因型CC、CG、GG在肺癌组的分布频率分别为29.07%、47.05%、23.87%,在对照组的分布频率分别为20.42%、51.9%、27.68%,两组无显著性差异(P=0.053)。肺癌组中C等位基因和CC基因型的分布均显著高于对照组(P<0.05)。rs9904341多态性与晚期NSCLC患者铂类药物化疗有效率无显著相关性,但与临床受益率相关,GG基因型携带者的临床受益率是CC基因型者的2.06倍(95%CI:0.71～5.97,P=0.184)。对289例肺癌患者生存分析显示,CC基因型肺癌患者较CG+GG基因型预后差(95%CI:1.11～2.6,P=0.015)。[结论]rs9904341多态性与肺癌的发病风险、预后及晚期NSCLC患者铂类药物化疗临床受益率相关。更多还原

【Abstract】 [Purpose] To investigate the relationship of survivin gene promoter rs9904341 polymorphism with the risk of lung cancer and the effect of platinum-based chemotherapy on advanced NSCLC.[Methods] The genotypes of rs9904341 polymorphism in 289 lung cancer patients and 289 healthy person were analyzed by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) method.In those lung cancer patients,130 cases with advanced NSCLC only received platinum-based chemotherapy,the clinical response was evaluated after 2 cycles,and the relationship of gene promoter polymorphism with susceptibility and survival of lung cancer was analyzed.[Results] The genotype frequencies for CC,CG,GG were 29.07%,47.05%,23.87% in lung cancer group,and 20.42%,51.9%,27.68% in control group respectively.No significant difference in the distribution of survivin genotype was found between the two groups(P=0.053).The frequencies of the C allele and CC genotype in lung cancer patients were significantly higher than those in healthy person(P<0.05).Analysis of 130 advanced NSCLC patients with platinum-based chemotherapy showed that no significant correlation of the rs9904341 polymorphism with response rate,but there is a relationship with the clinical benefit rate.The clinical benefit rate in GG genotype was 2.06 times of the CC genotype(95%CI:071～5.97,P=0.184) with survival analysis for the 289 cases with lung cancer,compared with CG+GG genotypes,the CC genotype was significantly associated with poor survival(95%CI:1.11～2.6,P=0.015).[Conclusion] The rs9904341 polymorphism is closely associated with susceptibility and prognosis of lung cancer,and is significant association with clinical benefit response in advance NSCLC receiving platinum-based chemotherapy.更多还原